BioLineRx (BLRX) Income from Continuing Operations (2011 - 2025)
BioLineRx's (BLRX) quarterly Income from Continuing Operations came in at 2236000.0 in Q4 2025, up 29.84% year-on-year from 1722119.86 in Q4 2024, and down 128.86% quarter-over-quarter from 977000.0 in Q3 2025.
BioLineRx (BLRX) Income from Continuing Operations (2011 - 2025) Analysis & Trends
BioLineRx's Income from Continuing Operations history runs 14 years deep, the most recent figure standing at 2236000.0 for Q4 2025.
- On a quarterly basis, Income from Continuing Operations rose 29.84% year-over-year to 2236000.0 in Q4 2025; TTM through Dec 2025 was 2026000.0, a 78.03% increase from a year earlier, with the FY2025 full-year figure at 2026000.0, up 78.03% from the prior year.
- Income from Continuing Operations fell to 2236000.0 in Q4 2025 per BLRX's latest filing, from 977000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 5127000.0 in Q1 2025 and bottomed at 23057000.0 in Q4 2023.
- The 5-year median for Income from Continuing Operations is 6022500.0 (2021), against an average of 5824650.0.
- Biggest YoY gain for Income from Continuing Operations was 836.64% in 2025; the steepest drop was 533.92% in 2025.
- Year by year, Income from Continuing Operations stood at 8124000.0 in 2021, then sank by 30.21% to 10578000.0 in 2022, then slumped by 117.97% to 23057000.0 in 2023, then surged by 86.18% to 3187000.0 in 2024, then climbed by 29.84% to 2236000.0 in 2025.
- Per Business Quant, the three latest BLRX Income from Continuing Operations figures stand at 2236000.0 (Q4 2025), 977000.0 (Q3 2025), and 3940000.0 (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | BioLineRx | 7.21 Bn | 7.21 Bn | 154,000.00 | -2.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2.24 Mn |
| Sep 30, 2025 | -977,000.00 |
| Jun 30, 2025 | -3.94 Mn |
| Mar 31, 2025 | 5.13 Mn |
| Dec 31, 2024 | -3.19 Mn |
| Sep 30, 2024 | -6.25 Mn |
| Jun 30, 2024 | 908,000.00 |
| Mar 31, 2024 | -696,000.00 |
| Dec 31, 2023 | -23.06 Mn |
| Sep 30, 2023 | -11.21 Mn |
| Jun 30, 2023 | -8.14 Mn |
| Mar 31, 2023 | -7.39 Mn |
| Dec 31, 2022 | -10.58 Mn |
| Sep 30, 2022 | -6.70 Mn |
| Jun 30, 2022 | -7.14 Mn |
| Mar 31, 2022 | -5.83 Mn |
| Dec 31, 2021 | -8.12 Mn |
| Sep 30, 2021 | -5.90 Mn |
| Jun 30, 2021 | -6.14 Mn |
| Mar 31, 2021 | -5.03 Mn |